NICE rejects adjuvant use of breast cancer drug
Draft guidance dubs Perjeta ‘not cost effective’ Related items fromOnMedica NICE fast-tracks approval of new skin cancer treatment New breast cancer drug ‘unaffordable’ for NHS One in 10 children in phase I cancer trials respond to drugs Cancer strategies failed to improve one-year survival Genetic risk model could guide prostate cancer screening
Source: OnMedica Latest News - Category: UK Health Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Children | Genetics | National Institute for Health and Clinical Excelle | Prostate Cancer | Skin | Skin Cancer | UK Health